C1q Inhibits Immune Complex-Induced Interferon-α Production in Plasmacytoid Dendritic Cells A Novel Link Between C1q Deficiency and Systemic Lupus Erythematosus Pathogenesis

被引:146
作者
Lood, Christian [2 ]
Gullstrand, Birgitta [2 ]
Truedsson, Lennart [2 ]
Olin, Anders I. [2 ]
Alm, Gunnar V. [3 ]
Ronnblom, Lars [4 ]
Sturfelt, Gunnar
Eloranta, Maija-Leena [4 ]
Bengtsson, Anders A. [1 ]
机构
[1] Univ Lund Hosp, Rheumatol Sect, Dept Clin Sci, S-22362 Lund, Sweden
[2] Lund Univ, Lund, Sweden
[3] Swedish Univ Agr Sci, Uppsala, Sweden
[4] Uppsala Univ, Uppsala, Sweden
来源
ARTHRITIS AND RHEUMATISM | 2009年 / 60卷 / 10期
基金
瑞典研究理事会;
关键词
SURFACE-PLASMON RESONANCE; TOLL-LIKE RECEPTORS; IFN-ALPHA; GENE-EXPRESSION; AUTOIMMUNE-DISEASE; IN-VIVO; INDUCTION; COMPONENTS; CD93; DIFFERENTIATION;
D O I
10.1002/art.24852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. C1q deficiency is the strongest risk factor known for the development of systemic lupus erythematosus (SLE), since almost all humans with a genetic deficiency of C1q develop this disease. Low C1q serum concentration is also a typical finding in SLE during flares, emphasizing the involvement of C1q in SLE pathogenesis. Recent studies have revealed that C1q has a regulatory effect on Toll-like receptor-induced cytokine production. Therefore, we undertook this study to investigate whether C1q could regulate production of interferon-alpha (IFN alpha). Methods. Peripheral blood mononuclear cells (PBMCs) and plasmacytoid dendritic cells (PDCs) were stimulated with 3 known interferogenic stimuli and cultured with physiologic concentrations of C1q. IFN alpha production was determined by an immunoassay. Results. C1q significantly inhibited PBMC IFN alpha production induced by RNA-containing immune complexes (ICs), herpes simplex virus (HSV), and CpG DNA. C1q also inhibited PDC IFN alpha production induced by ICs and CpG DNA but increased PDC IFNa production induced by HSV. The regulatory role of C1q was not specific for IFN alpha but was also seen for interleukin-6 (IL-6), IL-8, and tumor necrosis factor alpha. We demonstrated binding of C1q to PDCs both by surface plasmon resonance interaction analysis and by flow cytometry, and we also demonstrated intracellular detection of 2 C1q binding proteins. Conclusion. Our findings contribute to the understanding of why C1q deficiency is such a strong risk factor for SLE and suggest an explanation for the up-regulation of the type I IFN system seen in SLE patients.
引用
收藏
页码:3081 / 3090
页数:10
相关论文
共 43 条
  • [21] Gene expression studies in systemic lupus erythematosus
    Mandel, M.
    Achiron, A.
    [J]. LUPUS, 2006, 15 (07) : 451 - 456
  • [22] Immunologically active autoantigens: The role of Toll-like receptors in the development of chronic inflammatory disease
    Marshak-Rothstein, Ann
    Rifkin, Ian R.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 : 419 - 441
  • [23] Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q
    McGreal, EP
    Ikewaki, N
    Akatsu, H
    Morgan, BP
    Gasque, P
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (10) : 5222 - 5232
  • [24] Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9
    Means, TK
    Latz, E
    Hayashi, F
    Murali, MR
    Golenbock, DT
    Luster, AD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) : 407 - 417
  • [25] cDNA cloning and primary structure analysis of C1qR(p), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro
    Nepomuceno, RR
    HenschenEdman, AH
    Burgess, WH
    Tenner, AJ
    [J]. IMMUNITY, 1997, 6 (02) : 119 - 129
  • [26] Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis
    Norsworthy, PJ
    Fossati-Jimack, L
    Cortes-Hernandez, J
    Taylor, PR
    Bygrave, AE
    Thompson, RD
    Nourshargh, S
    Walport, MJ
    Botto, M
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (06) : 3406 - 3414
  • [28] Pathogenesis of systemic lupus erythematosus (SLE)
    Robson, MG
    Walport, MJ
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (05) : 678 - 685
  • [29] RONNBLOM LE, 1990, J INTERN MED, V227, P207
  • [30] Selmi C, 2006, CURR OPIN INVEST DR, V7, P451